Boston Therapeutics (BTHE) to Present at Livingston Securities Advanced and Nano Life Sciences Summit

MissionIR would like to highlight Boston Therapeutics (OTCQB: BTHE), a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes.

In the company’s news,

Boston Therapeutics announced it will be making a presentation on a corporate update at the Livingston Securities Advanced and Nano Life Sciences Summit. The presentation is to be given by the President of Boston Therapeutics, Kenneth A. Tassey, Jr., on October 17, 2013, in New York City.

Mr. Tassey, Jr. will cover Boston Therapeutics’ product pipeline, including PAZ320. Other topics of discussion to be covered during the presentation include the company’s product to reduce post-meal glucose elevation as well as other corporate developments. The presentation will be available on Boston Therapeutics’ website: http://ir.stockpr.com/bostonti/overview.

Headquartered in Manchester, NH, Boston Therapeutics develops drugs that address diabetes using complex carbohydrate chemistry. Specifically the company is focused on development and commercialization of therapeutic molecules that address Type 2 diabetes. The company’s initial product pipeline consists of:

• PAZ320, a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.
• IPOXYN™, a glyco-protein based therapeutic agent using proprietary processes and patented technology. IPOXYN™ is an anti-necrosis drug that consists of a stabilized glycoprotein composition containing oxygen-rechargeable iron, targeting both human and animal tissues and organ systems deprived of oxygen and in need of metabolic support.
• OXYFEX™, a product that can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events.

The company is backed by a highly experienced and insightful management and scientific advisory team that has extensive expertise in complex carbohydrate chemistry, regulatory, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. Its executive management team has more than 100 years of combined experience.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

###